Tracy Sizemore
Family · Manchester, KYNPI 1184015042
Payments from drug & device makers
Across 300 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$898
- Novo Nordisk$843
- AstraZeneca$464
- GSK$419
- Lilly USA, LLC$399
- Merck$278
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,687100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 58 | $898 |
| Novo Nordisk | 53 | $843 |
| AstraZeneca | 15 | $464 |
| GSK | 33 | $419 |
| Lilly USA, LLC | 38 | $399 |
| Merck | 16 | $278 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $198 |
| Bayer | 8 | $148 |
| Medtronic | 7 | $141 |
| Dexcom, Inc. | 6 | $101 |
| Johnson & Johnson | 5 | $90 |
| Ardelyx, Inc. | 5 | $86 |
| Pfizer | 6 | $85 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $83 |
| Phathom Pharmaceuticals, Inc. | 9 | $64 |
| Novartis | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $49 |
| Astellas Pharma US Inc | 3 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $42 |
| Boehringer Ingelheim | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Nestle Healthcare Nutrition Inc. | 2 | $27 |
| Insulet Corporation | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Amgen | 1 | $23 |
| Radius Health, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$135
How this compares
$4,687 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 108 | $87,531 |
| MounjaroTirzepatide | 71 | $76,444 |
| OzempicSemaglutide | 69 | $74,662 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 79 | $50,920 |
| EliquisApixaban | 79 | $49,502 |
| Ondansetron Hcl | 85 | $33,167 |
| VascepaIcosapent Ethyl | 73 | $30,396 |
| FarxigaDapagliflozin Propanediol | 47 | $28,314 |
| RybelsusSemaglutide | 25 | $27,363 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $27,114 |
| Spiriva RespimatTiotropium Bromide | 33 | $17,086 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $16,030 |
| KerendiaFinerenone | 24 | $15,543 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $15,360 |
| LinzessLinaclotide | 25 | $13,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $32 | $113,024155 claims |
| Novo NordiskOzempic, Rybelsus | $843 | $102,02694 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $464 | $85,348154 claims |
| Lilly USA, LLCMounjaro | $399 | $76,44471 claims |
| PfizerEliquis | $85 | $49,50279 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $419 | $42,47475 claims |
| AbbVieLinzess, Creon | $898 | $22,95737 claims |
| BayerKerendia | $148 | $15,54324 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $11,98611 claims |
| MerckJanuvia | $278 | $8,44513 claims |
| Sanofi-aventis U.S. LLCLantus | $30 | $2,36212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.
Other family in Manchester
- Eva EdwardsManchester$14K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.